Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
ADC ID |
DRG0IKJTH
|
|||||
---|---|---|---|---|---|---|
ADC Name |
LCB14-0648
|
|||||
Synonyms |
LCB14 0648; ADC14-0610
Click to Show/Hide
|
|||||
Organization |
LegoChem Biosciences, Inc.
|
|||||
Drug Status |
Investigative
|
|||||
Indication |
In total 1 Indication(s)
Burkitt lymphoma [ICD11:2A85]
Investigative
|
|||||
Drug-to-Antibody Ratio |
2
|
|||||
Structure | ||||||
Antibody Name |
Anti-CD19 mAb DI-B4
|
Antibody Info | ||||
Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
Payload Name |
Monomethyl auristatin F
|
Payload Info | ||||
Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
Linker Name |
LCB14-0648 linker
|
|||||
Conjugate Type |
Site-specific conjugation through the CaaX sequence at the C-terminal.
|
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 80.97% (Day 21) | Positive CD19 expression (CD19 +++/++) | ||
Method Description |
6-week old female irradiated Balb/c nude mice were subcutaneously injected with 5x106 Ramos cells. After two weeks, tumor volume reached about 130 mm, and micewere randomly divided into groups of 10. Mice were then injected intravenously with 2 mg/kg of ADC or unconjugated antibody or vehicle (PBS).
|
||||
In Vivo Model | Ramos CDX model | ||||
In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 85.16% (Day 21) | Positive CD19 expression (CD19 +++/++) | ||
Method Description |
6-week old female irradiated Balb/c nude mice were subcutaneously injected with 5x106 Ramos cells. After two weeks, tumor volume reached about 130 mm, and micewere randomly divided into groups of 10. Mice were then injected intravenously with 5 mg/kg of ADC or unconjugated antibody or vehicle (PBS).
|
||||
In Vivo Model | Ramos CDX model | ||||
In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 88.70% (Day 21) | Positive CD19 expression (CD19 +++/++) | ||
Method Description |
6-week old female irradiated Balb/c nude mice were subcutaneously injected with 5x106 Ramos cells. After two weeks, tumor volume reached about 130 mm, and micewere randomly divided into groups of 10. Mice were then injected intravenously with 10 mg/kg of ADC or unconjugated antibody or vehicle (PBS).
|
||||
In Vivo Model | Ramos CDX model | ||||
In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 110 ng/mL | Positive CD19 expression (CD19 +++/++) | ||
Method Description |
Raji cells were seeded in a 96-wellplate at 200,000 cells/well in 100 pL of growth media. The cells were incubated at 37°C in 5% CO2, for 1 day. Serial dilutions of anti-CD19 ADC from 4.0 ug/mL to 1.5625 ng/mL in 100 pL media were added tothe wells, and the cells were incubated with the antibodies for 72 hours.
|
||||
In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 10.00 ug/mL | Negative CD19 expression (CD19 -) | ||
Method Description |
K562 cells were seeded in a 96-wellplate at 200,000 cells/well in 100 pL of growth media. The cells were incubated at 37°Cin 5% CO2, for 1 day. Serial dilutions of anti-CD19 ADC from 4.0 ug/mL to 1.5625 ng/mL in 100 pL media were added tothe wells, and the cells were incubated with the antibodies for 72 hours.
|
||||
In Vitro Model | Chronic myeloid leukemia | K562 cells | CVCL_0004 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.